MITF–TFEC Regulation in B Cells for Autoimmune Tolerance

Solution Overview

Problem

Current treatments for autoimmune diseases often involve broad immunosuppression, leading to serious side effects and increased susceptibility to infections and malignancies, and many patients do not respond adequately to existing therapies, necessitating a need for novel therapeutic approaches that can achieve sustained, treatment-free remission while minimizing long-term toxicities.

Innovation Solution

The method involves targeting the Tfec transcription factor in B lymphocytes to regulate the balance between Mitf and Tfec transcription factors using engineered zinc finger proteins, CRISPR-guided base editing, or RNA-targeted therapeutics to either decrease Tfec activity or increase Mitf expression, thereby restoring immune tolerance in self-reactive B cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If broad immunosuppression is used to treat autoimmune diseases, then immune system activity is suppressed, but susceptibility to infections and malignancies increases and treatment response is inadequate

Engineering Contradiction:

Improveautoimmune activityVSAvoidsusceptibility to infections and malignancies

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies local quality by specifically targeting Tfec transcription factor activity in B lymphocytes rather than implementing broad immunosuppression. This localized approach modulates autoimmune activity in the specific cell type responsible for the pathology while preserving immune function in other cell types, thereby avoiding increased susceptibility to infections and malignancies that characterizes broad immunosuppressive therapy

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by modulating the activity level of the Tfec transcription factor through pharmacological agents. By adjusting this specific molecular parameter in B cells, the therapy achieves adequate treatment response in autoimmune diseases while maintaining appropriate immune surveillance and function, thus avoiding the inadequate response and high infection risk associated with broad immunosuppression

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If current immunosuppressive therapies are used, then treatment response is achieved, but long-term toxicities and side effects increase

Engineering Contradiction:

Improveautoimmune disease activityVSAvoidlong-term toxicities and side effects

Core Design Contradiction:

Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by specifically targeting Tfec transcription factor activity in B lymphocytes rather than implementing broad immunosuppression. This localized approach modulates autoimmune activity in the specific cell type responsible for the pathology while preserving immune function in other cell types, thereby avoiding increased susceptibility to infections and malignancies that characterizes broad immunosuppressive therapy

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs self-service by utilizing the endogenous Tfec transcription factor and its natural regulatory pathways within B cells. By modulating this intrinsic regulatory mechanism rather than introducing external immunosuppressive agents, the therapy achieves disease control while minimizing long-term toxicities and side effects associated with conventional immunosuppressive medications

Inventive Principle:

Principle #25Self-service

3Object-affected harmful factors

If existing therapies are used to treat autoimmune diseases, then some symptom relief is achieved, but sustained treatment-free remission is not achieved

Engineering Contradiction:

Improveautoimmune disease symptomsVSAvoidduration of remission

Core Design Contradiction:

Object-affected harmful factorsVSDuration of action of stationary object

Solution Approach 1:

The patent employs parameter changes by modulating the activity level of the Tfec transcription factor through pharmacological agents. By adjusting this specific molecular parameter in B cells, the therapy achieves adequate treatment response in autoimmune diseases while maintaining appropriate immune surveillance and function, thus avoiding the inadequate response and high infection risk associated with broad immunosuppression

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250241984A1Targetting activity of the MITF family as a therapeutic for regulating gene expression networks implicated in b cell homeostasis, germinal center responses, and tolerance

Publication Date: 2025.07.31 THE RES FOUNDATION FOR THE STATE UNIV OF NEW YORK

AI summary

The microphthalmia transcription factor Mitf has been shown to regulate B cell activation and tolerance. However, the underlying B cell-specific mechanisms responsible, and those that distinguish Mitf from closely related Mitf/TFE (MiT) transcription factors Tfe3, Tfeb, and Tfec, remain obscure. Two complementary mouse models of Mitf and B-cell specific MiT family deficiency were used to define how MiT family candidate target genes and pathway dysregulation can occur in pathogenic B cells due to Tfec-like overexpression and subsequent loss-of-protective functions of Mitf for autoimmune tolerance. These findings underscore the critical role of Mitf in maintaining B cell homeostasis and self-tolerance, and highlight the potential for therapeutics to either decrease the functionality of Tfec and/or increase the functionality of Mitf to treat autoimmune diseases.